European Journal of Biomedical and Pharmaceutical Sciences

A COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF FIXED DOSE COMBINATION OF BIMATOPROST/TIMOLOL WITH DORZOLAMIDE/TIMOLOL IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA.

Kriti Malhotra, P. K. Agarwal* and Ruchika Agarwal

ABSTRACT

Fixed-combination ocular hypotensives have well tried advantages over monotherapy. This study compares the safety and efficacy of fixed-combination bimatoprost/timolol (BTFC) and Dorzolamide/timolol (DTFC) in patients with primary open-angle glaucoma or ocular hypertension. In this parallel study, sixty patients with raised intraocular pressure (IOP) received once-daily BTFC or twice-daily DTFC medication for twelve weeks. IOP was evaluated at 9 am and 12 pm at weeks 2, 4 and 6. Primary endpoint was mean IOP change at the end of the therapy. At week 12, statistically significant IOP reductions from baseline were observed in both BTFC and DTFC (P < 0.001) groups, regardless of assessment time. BTFC group showed greater significant decrease in mean IOP than DTFC at 12 weeks (P < 0.001). Both drug combinations were safe and well tolerated. Once-daily BTFC demonstrated to have greater IOP-lowering efficacy clinically.

Keywords: Ocular hypertension, Bimatoprost.